Back to Headlines
Health
Jun 04, 2026
Analyzed by GPT OSS 120B

Ebola’s Bundibugyo Strain Spurs $60m Vaccine Race: Candidates, Treatments, and Timeline

AI Summary
Three vaccine developers have secured $60 million in emergency funding to combat the Bundibugyo strain of Ebola spreading in the DRC and Uganda. With candidates from IAVI, Oxford University, and Moderna, timelines range from a few months to nine months, while security challenges threaten trial deployment.

Emergency Funding Fuels Three Vaccine Candidates

The Coalition for Epidemic Preparedness Innovations (CEPI) announced $60 million in emergency grants to fast‑track three vaccine programmes targeting the Bundibugyo strain of Ebola. The funding is split among IAVI, Oxford University (in partnership with the Serum Institute of India), and Moderna, each racing to move from pre‑clinical work to human trials.

Projected Timelines for Vaccine Trials

  • IAVI vaccine: WHO labels it the “most promising candidate”. Expected to enter clinical trials in seven to nine months, though IAVI aims to accelerate.
  • Oxford vaccine (ChAdOx1 Bundibugyo): Leveraging the same platform as the Oxford/AstraZeneca COVID‑19 jab, trials could start within two to three months pending animal data.
  • Moderna vaccine: mRNA‑based candidate not yet on WHO’s list; pre‑clinical work could allow trial initiation within months after CEPI’s additional $50 million commitment.

Financial Commitments and Their Significance

The combined $110 million from CEPI ($60 million emergency grant + $50 million for Moderna) underscores the urgency of a coordinated response. These funds cover pre‑clinical development, manufacturing scale‑up, and the logistical costs of conducting trials in a conflict‑affected region.

Operational Challenges in the DRC and Uganda

Security instability in eastern DRC—where militias have attacked Ebola treatment centres—has hampered trial set‑up and patient recruitment. Researchers, including Dr Richard Hatchett (CEPI CEO), stress that “every day counts” but note that safe trial execution depends on stabilising the environment and securing community trust.

Potential Therapeutic Options Beyond Vaccines

  • Monoclonal antibodies MBP134 and Maftivimab show promise in early studies.
  • The antiviral remdesivir is being evaluated for efficacy against Bundibugyo.
  • A novel prevention pill, obdeldesivir, demonstrated up to 100 % protection in monkey models when administered daily for ten days.

Outlook: When Might Effective Countermeasures Arrive?

If security conditions improve, the Oxford candidate could enter Phase 1 trials by late summer 2026, while IAVI’s schedule may see first‑in‑human dosing by early 2027. Moderna’s mRNA platform could follow a similar timeline, contingent on pre‑clinical results. Successful trials could lead to emergency use authorisations within a year of dosing, offering the first targeted tools against the Bundibugyo strain and informing preparedness for future Ebola outbreaks.